Multiple myeloma : retrospective analysis from a Tertiary Centre

Ayyappan C P, Kalaichelvi K, Suresh Kuma .

Abstract


Forty one patients with myeloma were                      retrospectively analyzed.  Incidence was high in men. Median age was 51 years. Twenty nine (71%) patients were farmers and  12(29%) were  painters, carpenters and weavers. Most common  symptoms was bone pain (68.3%), neurological deficit (12.2%), and low backache (12.2%) Hypercalcemia was seen in 2(11%) patients. Renal failure was seen in 3(7.3%) patients, anemia in 35( 87%) patients below 10.0 g/dl and multiple bony lesions in 21(51%) was seen at presentation. Serum protein electrophoresis was positive in 30(75%) patients. The plasma cell burden in bone marrow  biopsies was  more than 20%   in 41(100%) patients  at diagnosis. As per Durie salmon staging system, Twenty one (51%) patients were in stage IIA, 17(41.5%) in stage IIIA and 3(7.3% ) in stage IIIB. The patients were treated with induction               regimen either BDT(18) or CVP-T(13 ) regimen and  followed by thalidomide based maintenance regimen. Two year overall survival  rate was 43% and median overall survival was 26 months. 


Full Text:

PDF

References


M.S. Raab, K. Podar, I. Breitkreutz, Multiple myeloma, Lancet, 374(9686), 2009, 324-39.

SEER data Available from http://seer.cancer.gov [September 12, 2016 ].

Globocan data 2012 access from online.

D.A. Riedel, L.M. Pottern, The epidemiology of multiple myeloma, Hematol Oncol. Clin. North Am., 6( ), 1992, 225 .

M. Ichimaru, T. Ishimaru, M. Mikami, M. Matsunaga, Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950–76: relationship to radiation dose absorbed by marrow, J. Natl. Cancer Inst. 69( )1982, 323 .

D.E. Bergsagel, O. Wong, P.L. Bergsagel, Benzene and multiple myeloma: appraisal of thescientific evidence, Blood 94( ), 1999, 1174 .

I. Lundberg, R. Milatou-Smith, Mortality and cancer incidence among Swedish paint industry workers with long-term exposure to organic solvents, Scand J Work Environ Health 24( ), 1998, 270.

S.E. Salmon, R.A. Kyle, Silicone gels, induction of plasma cell tumors and genetic susceptibility in mice: a call for epidemiologic investigation of women with silicone breast, J Natl Cancer Inst 86( ), 1994, 1040.

M.M. Doody, M.S. Linet, A.G. Glass, Risks of non-Hodgkin’s lymphoma, multiple myeloma, and leukemia associated with common medications, Epidemiology, 7( ), 1996, 131 .

M.S. Linet, S.D. Harlow, J.K. McLaughlin, A case-control study of multiple myeloma in whites:chronic antigenic stimulation, occupation, and drug use, Cancer Res. 47( ), 1987, 2978 .

L.M. Brown, M.S. Linet, R.S. Greenberg, Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer, 85( ), 1999, 2385.

B. Grosbois, P. Jego, M. Attal, Familial multiple myeloma: report of fifteen families. Br J Haematol, 105( ), 1999, 768 .

L.M. Brown, G. Gridley, D. Check, O. Landgren, Risk of multiple myeloma and monoclonalgammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders, Blood, 111( ), 2008, 3388

R. Griniute, I.A. Bumblyte, Clinical and laboratory features and prognostic implications in myeloma with and without renal impairment, Medicina (Kaunas) 39( ), 2003, 41-7.

R.A. Kyle, M.A. Gertz, T.E. Witzig, J.A. Lust, M.Q. Lasy, A. Dispensieri, Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin. Proc., 78( ), 2003, 21-33.

P. Gupta, V. Kochupillai, A 12 tears study of multiple myeloma at AIIMS. Ind J Med & Ped Oncol., 16( ), 1995, 108-114.

M.C. Alavanja, D.P. Sandler, C.F. Lynch, Cancer incidence in the agricultural health study, Scand J Work Environ Health, 31( ), 2005, 39-45.

P. Boffetta, S.D. Stellman, L. Garfinkel, A case-control study of multiple myeloma nested in the American Cancer Society prospective study, Int J Cancer, 43( ), 1989, 554 .

Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128.

Wang M ,Delasalle K, Giralt S,et al.Rapid control of previously untreated Multiple Myeloma with Bortezomib –Thalidomide –Dexamethasone followed by early intensive therapy .Blood .2005;106 abstract 784.

Kaur P et al,Multiple myeloma :A clinical and pathological profile. G J O .issue 16,2014.

Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia2007;21:151–157


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An initiative of The Tamil Nadu Dr M.G.R. Medical University